KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 0.23.

  • Halozyme Therapeutics' Equity Ratio rose 614.07% to 0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.23, marking a year-over-year increase of 614.07%. This contributed to the annual value of 0.18 for FY2024, which is 26464.38% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Equity Ratio stood at 0.23 for Q3 2025, which was up 614.07% from 0.16 recorded in Q2 2025.
  • Halozyme Therapeutics' Equity Ratio's 5-year high stood at 0.24 during Q3 2021, with a 5-year trough of 0.04 in Q1 2023.
  • Its 5-year average for Equity Ratio is 0.14, with a median of 0.15 in 2024.
  • In the last 5 years, Halozyme Therapeutics' Equity Ratio tumbled by 8269.6% in 2023 and then surged by 26464.38% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Equity Ratio (Quarter) stood at 0.18 in 2021, then crashed by 48.29% to 0.09 in 2022, then tumbled by 47.56% to 0.05 in 2023, then surged by 264.64% to 0.18 in 2024, then grew by 28.67% to 0.23 in 2025.
  • Its Equity Ratio stands at 0.23 for Q3 2025, versus 0.16 for Q2 2025 and 0.22 for Q1 2025.